title: Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9.
abstract: OBJECTIVE
  To describe the procedures and reproducibility for grading stereoscopic color fundus photographs and fluorescein angiograms of participants in the SCORE Study.
  
  
  METHODS
  Standardized stereoscopic fundus photographs and fluorescein angiograms taken at 84 clinical centers were evaluated by graders at a central reading center. Type of retinal vein occlusion (RVO), area of retinal thickening, and area of retinal hemorrhage are evaluated from fundus photographs; area of fluorescein leakage and area of capillary nonperfusion are measured on fluorescein angiography. Temporal reproducibility consisted of annual regrading of a randomly selected dedicated subset of fundus photographs (60 subjects) and fluorescein angiograms (40 subjects) for 3 successive years. Contemporaneous reproducibility involved monthly regrading of a 5% random selection of recently evaluated fundus photographs (n = 73).
  
  
  RESULTS
  The intergrader agreement for RVO type and presence of retinal thickening was greater than 90% in the 3 annual regrades. The intraclass correlation (ICC) for area of retinal thickening in the 3 years ranged from 0.39 to 0.64 and for area of retinal hemorrhage, 0.87 to 0.96. The ICC for area of fluorescein leakage ranged from 0.66 to 0.75 and for capillary nonperfusion, 0.94 to 0.97. The contemporaneous reproducibility results were similar to those of temporal reproducibility for all variables except area of retinal thickening (ICC, 0.84).
  
  
  CONCLUSIONS
  The fundus photography and fluorescein angiography grading procedures for the SCORE Study are reproducible and can be used for multicenter longitudinal studies of RVO. A systematic temporal drift occurred in evaluating area of retinal thickening.
authors.affiliation: Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53705-3611, USA.
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Blodi
authors.forename: Amitha
authors.initials: A
authors.lastname: Domalpally
authors.forename: Ingrid U
authors.initials: IU
authors.lastname: Scott
authors.forename: Michael S
authors.initials: MS
authors.lastname: Ip
authors.forename: Neal L
authors.initials: NL
authors.lastname: Oden
authors.forename: Julee
authors.initials: J
authors.lastname: Elledge
authors.forename: Kelly
authors.initials: K
authors.lastname: Warren
authors.forename: Michael M
authors.initials: MM
authors.lastname: Altaweel
authors.forename: Judy E
authors.initials: JE
authors.lastname: Kim
authors.forename: Paul C
authors.initials: PC
authors.lastname: Van Veldhuisen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005451:Fluorescein Angiography / Q000379:methods*; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000145:classification / Q000188:drug therapy / Q000209:etiology; D015588:Observer Variation; D010781:Photography / Q000379:methods*; D011786:Quality Control; D015203:Reproducibility of Results; D012160:Retina / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000145:classification* / Q000150:complications / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage; D014822:Vitreous Body
chemical_list: D005938:Glucocorticoids; D014222:Triamcinolone Acetonide